Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?

CEL-SCI Corporation CVM announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the U.K. 

The NICE briefing includes the following statements:

• "The LI injection [Multikine] utilizes naturally occurring, immune-regulating cytokines, and could be the first investigational immunotherapeutic to be used in locally advanced SCCHN."
• "Results from phase III clinical trial indicated a statistically significant 5-year survival benefit with LI immunotherapy produced in patients receiving surgery plus radiotherapy, representing approximately 40% of the study population."
• "If licensed, LI [Multikine] will offer the first-line neoadjuvant treatment in previously untreated patients with SCCHN prior to standard of care."

"We are highly encouraged that NICE has selected Multikine for evaluation as a potential new standard of care for head and neck cancer. This is a big step forward in the UK," stated CEL-SCI CEO Geert Kersten.

Price Action: CVM shares are up 41% at $2.92 on the last check Monday.

Photo Via Company